European Commission Approves New Multiple Myeloma Treatment Delivery Method

The European Commission has granted approval for Sanofi's Sarclisa subcutaneous formulation, intended for the treatment of multiple myeloma. This new method utilizes an on-body injector, marking the first time an anticancer treatment in the EU will be delivered this way. The approval aims to provide patients and healthcare providers with greater flexibility for administration, allowing for use in both home and outpatient settings.